| Nov 13 |
Acrivon Therapeutics GAAP EPS of -$0.59
|
| Nov 13 |
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
|
| Oct 17 |
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
|
| Oct 16 |
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 12 |
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
|
| Oct 11 |
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
|
| Sep 18 |
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
|
| Sep 14 |
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
|
| Sep 10 |
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
|
| Sep 9 |
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
|
